Oculis Holding AG [OCS] vs Dyne Therapeutics [DYN] Detailed Stock Comparison

Oculis Holding AG

NASDAQ
Loading...

Dyne Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Oculis Holding AG wins in 9 metrics, Dyne Therapeutics wins in 5 metrics, with 1 ties. Oculis Holding AG appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricOculis Holding AGDyne TherapeuticsBetter
P/E Ratio (TTM)63.63-3.88Dyne Therapeutics
Price-to-Book Ratio6.432.61Dyne Therapeutics
Debt-to-Equity Ratio0.7221.19Oculis Holding AG
PEG Ratio-16.23-0.10Oculis Holding AG
EV/EBITDA-10.05-2.95Oculis Holding AG
Profit Margin (TTM)0.00%0.00%Tie
Operating Margin (TTM)-7,957.09%0.00%Dyne Therapeutics
Return on Equity-83.96%-61.32%Dyne Therapeutics
Return on Assets (TTM)-29.71%-35.45%Oculis Holding AG
Free Cash Flow (TTM)$-59.97M$-294.75MOculis Holding AG
1-Year Return24.65%-62.43%Oculis Holding AG
Price-to-Sales Ratio (TTM)1,203.59N/AN/A
Enterprise Value$955.21M$1.30BDyne Therapeutics
EV/Revenue Ratio995.12N/AN/A
Revenue per Share (TTM)$0$0Oculis Holding AG
Earnings per Share (Diluted)$-2.91$-3.88Oculis Holding AG
Beta (Stock Volatility)0.131.08Oculis Holding AG
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Oculis Holding AG vs Dyne Therapeutics Stock Performance Analysis

Loading Price Chart...

Oculis Holding AG
Dyne Therapeutics
Oculis Holding AG Stock Overview | Dyne Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Oculis Holding AG5.61%5.82%7.59%-0.96%29.16%9.63%
Dyne Therapeutics-3.14%2.26%-4.89%54.65%68.89%-50.31%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Oculis Holding AG24.65%87.10%91.54%91.54%91.54%91.54%
Dyne Therapeutics-62.43%-4.09%-27.38%-44.52%-44.52%-44.52%

News Based Sentiment: Oculis Holding AG vs Dyne Therapeutics

Oculis Holding AG

News based Sentiment: POSITIVE

The positive Phase 2 trial results for Privosegtor are a significant development for Oculis, potentially opening the door to a new treatment for acute optic neuritis. However, the 'Very High' uncertainty rating from Morningstar underscores the inherent risks associated with pharmaceutical development, creating a mixed but overall positive narrative for the month.

View Oculis Holding AG News Sentiment Analysis

Dyne Therapeutics

News based Sentiment: POSITIVE

October was a strong month for Dyne Therapeutics, highlighted by key regulatory approvals (FDA Breakthrough Therapy and Japanese Orphan Drug designation) for DYNE-251, coupled with positive analyst upgrades and insider buying activity. While the company remains pre-revenue, these developments signal significant progress and potential for future growth, making it a noteworthy investment story.

View Dyne Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Oculis Holding AG vs Dyne Therapeutics

MetricOCSDYN
Market Information
Market Cap i$919.54M$1.95B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i28,1202,426,520
90 Day Avg. Volume i20,6302,473,740
Last Close$18.56$12.65
52 Week Range$13.60 - $23.08$6.36 - $35.90
% from 52W High-19.61%-64.76%
All-Time High$23.08 (Jan 13, 2025)$47.45 (Aug 19, 2024)
% from All-Time High-19.58%-73.34%
Growth Metrics
Quarterly Revenue Growth0.07%N/A
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-79.57%0.00%
Return on Equity (TTM) i-0.84%-0.61%
Debt to Equity (MRQ) i0.7221.19
Cash & Liquidity
Book Value per Share (MRQ)$2.73$5.00
Cash per Share (MRQ)$3.06$4.81
Operating Cash Flow (TTM) i$-70,665,524$-359,560,000
Levered Free Cash Flow (TTM) i$-28,741,479$-222,398,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Oculis Holding AG vs Dyne Therapeutics

MetricOCSDYN
Price Ratios
P/E Ratio (TTM) i63.63-3.88
Forward P/E i-7.84-4.13
PEG Ratio i-16.23-0.10
Price to Sales (TTM) i1,203.59N/A
Price to Book (MRQ) i6.432.61
Market Capitalization
Market Capitalization i$919.54M$1.95B
Enterprise Value i$955.21M$1.30B
Enterprise Value Metrics
Enterprise to Revenue i995.12N/A
Enterprise to EBITDA i-10.05-2.95
Risk & Other Metrics
Beta i0.131.08
Book Value per Share (MRQ) i$2.73$5.00

Financial Statements Comparison: Oculis Holding AG vs Dyne Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)OCSDYN
Revenue/Sales i$0$0
Cost of Goods Sold iN/AN/A
Gross Profit iN/AN/A
Research & Development i$18.73M$99.24M
Operating Income (EBIT) i$-26.09M$-115.79M
EBITDA i$-25.30M$-110.26M
Pre-Tax Income i$-31.91M$-110.86M
Income Tax i$-30,153N/A
Net Income (Profit) i$-31.88M$-110.86M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)OCSDYN
Cash & Equivalents i$80.74M$472.26M
Total Current Assets i$208.82M$689.50M
Total Current Liabilities i$45.92M$33.88M
Long-Term Debt i$904,615$18.22M
Total Shareholders Equity i$179.79M$668.97M
Retained Earnings i$-432.39M$-1.07B
Property, Plant & Equipment i$2.01M$34.19M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)OCSDYN
Operating Cash Flow i$-18.69M$-110.37M
Capital Expenditures i$-158,307$-981,000
Free Cash Flow i$-21.82M$-106.87M
Debt Repayment i$-91,717N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricOCSDYN
Shares Short i10,94215.30M
Short Ratio i0.796.78
Short % of Float i0.00%0.12%
Average Daily Volume (10 Day) i28,1202,426,520
Average Daily Volume (90 Day) i20,6302,473,740
Shares Outstanding i54.86M102.32M
Float Shares i41.34M122.63M
% Held by Insiders i0.06%0.00%
% Held by Institutions i0.31%0.95%

Dividend Analysis & Yield Comparison: Oculis Holding AG vs Dyne Therapeutics

MetricOCSDYN
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A